Inovio Pharmaceuticals In... (INO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Inovio Pharmaceuticals Statistics
Share Statistics
Inovio Pharmaceuticals has 36.10M shares outstanding. The number of shares has increased by 54.47% in one year.
Shares Outstanding | 36.10M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 39.04% |
Owned by Institutions (%) | n/a |
Shares Floating | 35.80M |
Failed to Deliver (FTD) Shares | 19.34K |
FTD / Avg. Volume | 2.15% |
Short Selling Information
The latest short interest is 3.50M, so 9.71% of the outstanding shares have been sold short.
Short Interest | 3.50M |
Short % of Shares Out | 9.71% |
Short % of Float | 9.82% |
Short Ratio (days to cover) | 11.22 |
Valuation Ratios
The PE ratio is -1 and the forward PE ratio is -1.39.
PE Ratio | -1 |
Forward PE | -1.39 |
PS Ratio | 163.1 |
Forward PS | 2.8 |
PB Ratio | 1.16 |
P/FCF Ratio | -1.09 |
PEG Ratio | n/a |
Enterprise Valuation
Inovio Pharmaceuticals Inc. has an Enterprise Value (EV) of 151.60M.
EV / Earnings | -1.12 |
EV / Sales | 182.21 |
EV / EBITDA | -1.16 |
EV / EBIT | -1.05 |
EV / FCF | -1.22 |
Financial Position
The company has a current ratio of 3.6, with a Debt / Equity ratio of 0.26.
Current Ratio | 3.6 |
Quick Ratio | 3.6 |
Debt / Equity | 0.26 |
Total Debt / Capitalization | 20.47 |
Cash Flow / Debt | -4.12 |
Interest Coverage | -117.71 |
Financial Efficiency
Return on equity (ROE) is -1.15% and return on capital (ROIC) is -97.55%.
Return on Equity (ROE) | -1.15% |
Return on Assets (ROA) | -0.78% |
Return on Capital (ROIC) | -97.55% |
Revenue Per Employee | 6.55K |
Profits Per Employee | -1.06M |
Employee Count | 127 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -74.29% in the last 52 weeks. The beta is 0.83, so Inovio Pharmaceuticals 's price volatility has been higher than the market average.
Beta | 0.83 |
52-Week Price Change | -74.29% |
50-Day Moving Average | 3.3 |
200-Day Moving Average | 7.35 |
Relative Strength Index (RSI) | 39.63 |
Average Volume (20 Days) | 898.28K |
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 832.01K and earned -135.12M in profits. Earnings per share was -6.09.
Revenue | 832.01K |
Gross Profit | -2.67M |
Operating Income | -143.94M |
Net Income | -135.12M |
EBITDA | -130.39M |
EBIT | -143.94M |
Earnings Per Share (EPS) | -6.09 |
Balance Sheet
The company has 14.31M in cash and 30.21M in debt, giving a net cash position of -15.90M.
Cash & Cash Equivalents | 14.31M |
Total Debt | 30.21M |
Net Cash | -15.90M |
Retained Earnings | -1.62B |
Total Assets | 107.06M |
Working Capital | 67.79B |
Cash Flow
In the last 12 months, operating cash flow was -124.37M and capital expenditures -320.90K, giving a free cash flow of -124.69M.
Operating Cash Flow | -124.37M |
Capital Expenditures | -320.90K |
Free Cash Flow | -124.69M |
FCF Per Share | -5.62 |
Margins
Gross margin is -321.09%, with operating and profit margins of -17.30K% and -16.24K%.
Gross Margin | -321.09% |
Operating Margin | -17.30K% |
Pretax Margin | -16.24K% |
Profit Margin | -16.24K% |
EBITDA Margin | -15.67K% |
EBIT Margin | -17.30K% |
FCF Margin | -14.99K% |
Dividends & Yields
INO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -292.79% |
FCF Yield | -165.66% |
Analyst Forecast
The average price target for INO is $15, which is 621.2% higher than the current price. The consensus rating is "Buy".
Price Target | $15 |
Price Target Difference | 621.2% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 25, 2024. It was a backward split with a ratio of 1:12.
Last Split Date | Jan 25, 2024 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | 735.18 |
Piotroski F-Score | 1 |